REG - Physiomics PLC - Contract Award

PhysiomicsAnnouncement

17/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241017:nRSQ4715Ia&default-theme=true

RNS Number : 4715I  Physiomics PLC  17 October 2024

17 October 2024

 

Physiomics plc

("Physiomics" or the "Company")

 

Contract Award

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce that it has been
awarded a new contract by an existing client Cancer Research UK. The project
involves the development of Pharmacokinetic Pharmacodynamic (PK/PD)* model to
simulate the exposure-response relationship for a novel oncology therapy to
guide starting dose and dose range for an upcoming First in Human Study.

 

Dr Peter Sargent, CEO, commented: "We are delighted to have been awarded this
new contract with one of our existing clients. This contract reflects the
impact of the services we provide and our continued relationship with Cancer
Research UK".

 

* PKPD modelling is a scientific approach used to describe and predict the
relationship between drug concentration in the body (PK) and the corresponding
biological or physiological effect (PD). This supports the prediction of what
the optimum drug dose needs to be to enable a therapeutic effect whilst
minimising levels of toxicity.

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting-edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 100 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTGPGWWUUPCGWQ